did not reach statistical significance (1.3% in SIM and 3.4% in EAE, P =0.37) ( Table 3 ).
← all excerpts
Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients.
1
0.3700
0.3700